BMC medicine · 2025
Circulating transthyretin with atrial morpho-functional phenotypes and atrial fibrillation risk, and the modifying role of BMI.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Nan, Jia Ziheng, Zhao Jinhua, Han Xuyao, Liu Jie, Tse Gary, Zhou Jiandong, Chen Kang-Yin, Lip Gregory Y H, Liu Tong
Аннотация
BACKGROUND: Low circulating transthyretin (TTR) concentration has been suggested as a biomarker of transthyretin tetramer instability, a prerequisite for the development of transthyretin cardiac amyloidosis. This study aimed to evaluate the associations between circulating TTR levels with incident atrial fibrillation (AF) and other arrhythmias.
METHODS: This study used data from the UK Biobank. Participants with available TTR data and without prior arrhythmias were included. The primary outcome was new-onset AF. The secondary outcomes were new-onset supraventricular arrhythmias (SVA), bradyarrhythmias, cardiac block, and ventricular arrhythmias (VA). Multivariable Cox regression was applied to evaluate the associations between circulating TTR levels with arrhythmia outcomes.
RESULTS: A total of 40,723 participants (mean age 56.7 ± 8.2 years; 55% women) were included. After adjusting for potential confounders, one standard deviation (SD) decrease in TTR levels was associated with an increased risk of incident AF (HR 1.06, 95% CI 1.02-1.11). Furthermore, significant associations between low TTR with atrial structural remodeling were observed, manifesting as increased left atrial volume index (β 0.51, 95% CI 0.09-0.92) and right atrial volume index (β 0.87, 95% CI 0.39-1.40). In addition, there was a significant association between lower TTR levels with higher incident SVA risk, but not for bradyarrhythmias, cardiac block, or VA. A consistently significant interaction effect was identified between TTR levels and BMI for the risk of AF, SVA, bradyarrhythmias, and cardiac block (all Pinteraction < 0.05), with lower TTR levels being significantly associated with a higher risk of AF (HR 1.15, 95% CI 1.06-1.26), SVA (HR 1.15, 95% CI 1.06-1.25), bradyarrhythmias (HR 1.17, 95% CI 1.05-1.30), and cardiac block (HR 1.15, 95% CI 1.02-1.29) among individuals with a BMI < 25 kg/m2. In addition, carriers of likely pathogenic or pathogenic TTR variants (LP/P) had lower levels of plasma TTR compared with noncarriers, as well as higher arrhythmia risks, especially for non-Val142Ile carriers.
CONCLUSIONS: Lower circulating TTR concentrations were associated with higher risk of incident AF. Exposure to low TTR and low BMI may be associated with a higher risk of AF, SVA, bradyarrhythmias, and cardiac block.
METHODS: This study used data from the UK Biobank. Participants with available TTR data and without prior arrhythmias were included. The primary outcome was new-onset AF. The secondary outcomes were new-onset supraventricular arrhythmias (SVA), bradyarrhythmias, cardiac block, and ventricular arrhythmias (VA). Multivariable Cox regression was applied to evaluate the associations between circulating TTR levels with arrhythmia outcomes.
RESULTS: A total of 40,723 participants (mean age 56.7 ± 8.2 years; 55% women) were included. After adjusting for potential confounders, one standard deviation (SD) decrease in TTR levels was associated with an increased risk of incident AF (HR 1.06, 95% CI 1.02-1.11). Furthermore, significant associations between low TTR with atrial structural remodeling were observed, manifesting as increased left atrial volume index (β 0.51, 95% CI 0.09-0.92) and right atrial volume index (β 0.87, 95% CI 0.39-1.40). In addition, there was a significant association between lower TTR levels with higher incident SVA risk, but not for bradyarrhythmias, cardiac block, or VA. A consistently significant interaction effect was identified between TTR levels and BMI for the risk of AF, SVA, bradyarrhythmias, and cardiac block (all Pinteraction < 0.05), with lower TTR levels being significantly associated with a higher risk of AF (HR 1.15, 95% CI 1.06-1.26), SVA (HR 1.15, 95% CI 1.06-1.25), bradyarrhythmias (HR 1.17, 95% CI 1.05-1.30), and cardiac block (HR 1.15, 95% CI 1.02-1.29) among individuals with a BMI < 25 kg/m2. In addition, carriers of likely pathogenic or pathogenic TTR variants (LP/P) had lower levels of plasma TTR compared with noncarriers, as well as higher arrhythmia risks, especially for non-Val142Ile carriers.
CONCLUSIONS: Lower circulating TTR concentrations were associated with higher risk of incident AF. Exposure to low TTR and low BMI may be associated with a higher risk of AF, SVA, bradyarrhythmias, and cardiac block.